Skip to content

Furosemide Treatment Before Blood Transfusion in Patients With Systolic Dysfunction

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01705470
Enrollment
0
Registered
2012-10-12
Start date
2012-10-31
Completion date
2013-06-30
Last updated
2016-06-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anemia Treatment Among Patients Suffering From Left Ventricular Systolic Dysfunction

Keywords

Furosemide, Anemia, LV dysfunction, blood transfusion

Brief summary

The study Objective is to assess the clinical and echocardiographic changes of patients with systolic dysfunction receiving blood transfusion, with or without prior treatment with furosemide

Detailed description

More than 4 million patients receive a blood transfusion each year in the United States, many of them suffer from congestive heart failure. The reported prevalence of anemia in CHF is unknown, ranges widely from 4% to 70%, due to a lack of an established, consistent definition of anemia in CHF. Treating CHF patients with furosemide prior to blood transfusion became a common practice, even though no randomize clinical trial had examine this issue. Nand et al. measured the pulmonary capillary wedge pressures in 20 adults with chronic severe anemia (Hg \<6 mg/dl) and no systemic disease before and after transfusion of 700ml of whole blood. Ten of these patients were treated with furosemide (40 mg intra-venous) immediately prior the transfusion. The PCWP had increased significantly among patient who did not receive the furosemide and decreased by 3.75% among patients in the furosemide group, although this change was not was statistically significant. In another study, the same group of Nand et al. measured the PCWP among 40 chronic anemia patients receiving blood transfusion. None of the patients suffered from cardiopulmonary disease. The patients were randomly divided into 4 groups: the difference between the first 3 groups was the speed of the transfusion (2 ml/min, 5 ml/min and 10 ml/min). The fourth group patients were treated with 40 mg of furosemide before the transfusion was given in a rate of 5 ml/min. The PCWP increased significantly in the first 3 groups, with the rise being proportionately greater with faster transfusions (15.8, 20.9 and 32.2% in groups A, B and C, respectively). In the furosemide group, however, the PCWP decreased significantly by 21.7%.

Interventions

DRUGfurosemide

Sponsors

Tel-Aviv Sourasky Medical Center
Lead SponsorOTHER_GOV

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

* Subject is over 18 years old. * Documented ejection function equal to or over 40% in prior tests * The treating physician decided to treat the patient with packed cell

Exclusion criteria

* Known hypersensitivity to furosemide. * Calculated creatinine clearance over 20% (by MDRD) * Past adverse reaction to blood product.

Design outcomes

Primary

MeasureTime frameDescription
Diastolic echocardiographic changes following blood transfusion, with or without Furosemide treatmentWithin 4 hours from receiving the blood transfusionDiastolic echocardiographic variables, including Ea, E to Ea ratio, E to A ratio, and Pulmonary vein flow velocities, following blood transfusion, with or without Furosemide treatment

Secondary

MeasureTime frameDescription
clinical outcome following blood transfusion, with or without Furosemide treatmentWithin 4 hours from receiving the blood transfusionclinical outcome variables following blood transfusion, with or without Furosemide treatment, including the respiratory rate and oxygen saturation

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026